BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 24731807)

  • 1. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
    Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
    Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.
    Gallorini S; Taccone M; Bonci A; Nardelli F; Casini D; Bonificio A; Kommareddy S; Bertholet S; O'Hagan DT; Baudner BC
    Vaccine; 2014 Apr; 32(20):2382-8. PubMed ID: 24434044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
    Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
    J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
    Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
    BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
    Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
    Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets.
    Cherukuri A; Servat E; Woo J
    Vaccine; 2012 Jan; 30(2):237-46. PubMed ID: 22080173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
    Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
    Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P; Hedenskog M; Alves D; Brytting M; Schröder U; Linde A; Lundkvist A
    Vaccine; 2010 Sep; 28(39):6491-7. PubMed ID: 20637767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.